Elham Ali Ibrahim Elamin

Dr. Elham Ali Ibrahim Elamin

Hematology and Immunohematology, University of El Imam El Mahdi, Kūstī, White Nile, Sudan
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Life
Verified
Journal Article
Open access
PDF file
AEAhmed M E Elkhalifa
Ahmed M E Elkhalifa
MNMehak Nazar
Mehak Nazar
SASofi Imtiyaz Ali
Sofi Imtiyaz Ali
IKIbraq Khursheed
Ibraq Khursheed
STSyed Taifa
Syed Taifa
SNShowkat Ul Nabi
Showkat Ul Nabi
Diabetes mellitus (DM) is characterized by an absolute decline in insulin secretion and peripheral resistance and is the most prevalent metabolic and endocrine disorder. However, the pathogenesis of DM also includes adipocyte insulin resistance, increased glucagon secretion, increased renal glomerular glucose absorption, and neurotransmitter dysfunction. Although there is a wide spectrum of therapeutics available for glycemic control, owing to the identification of various pathogenic determinants of DM, management of DM remains challenging and complex. Current therapeutic interventions against DM focus mostly on glycemic control without considering the other pathological determinants that eventually lead to treatment failure and the progression of DM. Furthermore, long-term use of these conventionally available anti-diabetic drugs leads to various side effects, henceforth development of novel drugs against DM remains an unending search strategy for researchers. Various studies conducted in various parts of the world have proposed that these novel therapeutic interventions target multiple and alternate pathogenic hotspots involved in DM. The current review article discusses novel therapeutic options that hold particular promise to support their safety and discuss the side effects resulting from their use so that these novel candidate drugs can be effectively fabricated into potential drugs for the treatment of DM.

27 January 2024 in Heliyon
Verified
Journal Article
Open access
AEAhmed M.E. Elkhalifa
Ahmed M.E. Elkhalifa
SASofi Imtiyaz Ali
Sofi Imtiyaz Ali
SNShowkat Ul Nabi
Showkat Ul Nabi
IBImran Bashir
Imran Bashir
STSyed Taifa
Syed Taifa
AAAhmed M. Alzahrani
Ahmed M. Alzahrani
Regeneration is a rare occurrence in the animal kingdom, but the earthworm stands out as a remarkable example of this phenomenon. Recent research has highlighted the promising wound healing properties of extracts derived from earthworms. Therefore, we propose that earthworm granulation tissue extract (EGTE) may facilitate wound healing by regulating immune responses in a rabbit diabetic wound model. Electron microscopy reveals that 70 % EGTE possesses noteworthy porosity with spherical to irregularly oval configuration. Gas chromatography–mass spectrometry (GC–MS) Characterization of EGTE revealed higher levels of ergosta-5,7,22-trien-3-ol, (3. beta.,22E). In-Vitro studies revealed significant anti-oxidant, anti-inflammatory and anti-bacterial properties in dose dependent manner. Likewise, cytotoxicity assessments reveal that 70 % EGTE exhibits minimal harm to cells while displaying substantial antioxidant and anti-inflammatory activities. For In-Vivo studies excision wounds were created on the dorsal regions of the experimental animals and were divided as Group I (50 % EGTE), Group II (70 % EGTE), Group III (vehicle) and Group IV (distilled water). Over a 21-day observation period 70 % EGTE facilitated the early healing of wounds in the experimental animals, evident through prompt wound closure, granulation tissue formation, increased DNA content, enhanced tensile strength of the wound area and enhanced the expression/synthesis of wound healing markers/proteins. From these results it can be postulated that EGTE accelerates wound healing by immune modulation, dampening of inflammatory pathway and enhanced expression of growth markers. Henceforth making it promising candidate for therapeutic use in diabetic wound healing.

1 August 2023 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
AMAbdalmoneim M Magboul
Abdalmoneim M Magboul
EEElham Ali Ibrahim Elamin
Elham Ali Ibrahim Elamin
ATAbdelhakam G. Tamomh
Abdelhakam G. Tamomh
HMHafiz Y Mohammed
Hafiz Y Mohammed
MSMohammed Suliman
Mohammed Suliman
RAReem Ahmed
Reem Ahmed
Purpose: ABO blood group glycol-conjugate expression may influence human susceptibility to infection caused by Toxoplasma gondii. This study aimed to assess the relationship between blood group phenotypes as risk factors for toxoplasmosis and to correlate the prevalence of the disease with other risk factors. Materials and Methods: A total of two-hundred serum samples were collected from pregnant women referred for routine rotary examination in Rabak Teaching Hospital, White Nile State, Sudan, and examined for the parasite Toxoplasma gondii using the latex agglutination test. Results: The overall prevalence of toxoplasmosis in pregnant women (IgG positivity for T. gondii in the absence of IgM) was 41% (82/200). A higher prevalence of the infection was detected in women with blood group type AB 5 (55.6%) among the females in the AB blood group and the lowest in those with blood group type B 11 (35.5%). Those with a history of direct contact with cats reported the possibility of eating undercooked meat and soil-related potential risk factors (working in a garden with bare hands, eating unwashed vegetables and fresh fruits, poor handling of food) recorded 70 (82.4%), 59 (65.6%), 58 (77.3%), 73 (55.7%) and 70 (73.7%) of positive cases, respectively. Statistical analysis revealed a significant difference between Toxoplasma gondii infection and these risk factors. Conclusion: The study concluded that the ABO blood group system was not related to the absence or presence of anti-T. gondii antibodies in pregnant women in the study area. Contact with cat feces, raw meat consumption, and farming were identified as possible important risk factors for T. gondii infection within the study area.

23 May 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
SASofi Imtiyaz Ali
Sofi Imtiyaz Ali
AEAhmed M.E. Elkhalifa
Ahmed M.E. Elkhalifa
SNShowkat Ul Nabi
Showkat Ul Nabi
STSyed Taifa
Syed Taifa
ISIqra Hussain Shah
Iqra Hussain Shah
AAAhmed M. Alzahrani
Ahmed M. Alzahrani

1 December 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YGYing Gao
Ying Gao
EEElham Ali Ibrahim Elamin
Elham Ali Ibrahim Elamin
RZRongfang Zhou
Rongfang Zhou
HYHuili Yan
Huili Yan
SLShuang Liu
Shuang Liu
YZYueran Zhao
Yueran Zhao
FK506-binding protein 51 (FKBP51) is a member of the immunophilin family, with relevant roles in multiple signaling pathways, tumorigenesis and chemoresistance. However, the function of FKBP51 in papillary thyroid carcinoma (PTC) remains largely unknown. In the present study, increased FKBP51 expression was detected in PTC tissues as compared with adjacent normal tissues, and the expression level was associated with clinical tumor, node and metastasis stage. Using FKBP51-overexpressing K1 cells and FKBP51-knockdown TPC-1 cells, both human PTC cell lines, it was identified that FKBP51 promoted the migration and invasion of PTC, without affecting cell proliferation. Further investigation revealed that FKBP51 activated the NF-kappa B pathway and epithelial-to-mesenchymal transition (EMT) genes, and EMT was suppressed when NF-kappa B was inhibited. It was also assessed whether FKBP51 promoted the formation of cytoskeleton to promote migration and invasion of PTC using a tubulin tracker; however, no evidence of such an effect was observed. These results suggested that FKBP51 promotes migration and invasion through NF-kappa B-dependent EMT.

26 September 2014 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MYMahmoud Husni Ayesh (Haj Yousef)
Mahmoud Husni Ayesh (Haj Yousef)
ABAhnaf Bataineh
Ahnaf Bataineh
EEElham Ali Ibrahim Elamin
Elham Ali Ibrahim Elamin
Yousef KhaderYousef Khader
Yousef Khader
KAKhaldoon M Alawneh
Khaldoon M Alawneh
MRMohamad Rababah
Mohamad Rababah
We conducted this study to determine the erythrocyte glucose-6-phosphate dehydrogenase (G6PD) activity level in patients with end-stage renal disease (ESRD) on maintenance hemodialysis (HD) and to determine the effect of hemodialysis adequacy on G6PD activity levels and its impact on anemia. Eighty-two patients (48 men and 34 women) receiving regular hemodialysis for ESRD through arteriovenous fistulae for at least one year prior to the start of the study were enrolled in this study. G6PD activity levels were measured in all patients and the average Kt/V was used as a parameter of HD adequacy. Patients were divided into two groups according to Kt/V values. Group 1 included 45 patients with Kt/V˃1.2 (adequate HD), and group 2 included 37 patients with Kt/V˃1.2 (inadequate HD). The average hemoglobin level and the weekly dose of an erythropoietin-stimulating agent, epoetin alpha (ESA), for each patient were calculated for one year. The mean (SD) erythrocyte G6PD activity for all patients on hemodialysis was 7.64 ± 1.85 U/g Hb. Patients who had received adequate hemodialysis had a significantly higher average erythrocyte G6PD (mean (SD) = 9.2 ± 0.7 U/g Hb) compared to patients who had inadequate hemodialysis (mean (SD) = 5.7 ± 0.7U/g Hb) (P-value <0.005). The mean hemoglobin concentration was significantly higher in patients with adequate hemodialysis compared to those with inadequate hemodialysis. Our study demonstrated the beneficial effect of adequate hemodialysis in correcting anemia by enhancing the erythrocyte G6PD activity in patients.